Invivyd (IVVD) Non-Current Deferred Tax Liability (2023 - 2025)
Invivyd (IVVD) reported Non-Current Deferred Tax Liability of $719000.0 for Q4 2025, up 46.14% on a YoY basis from $492000.0 in Q4 2024, and up 46.14% quarter-over-quarter from $492000.0 in Q4 2024.
Invivyd (IVVD) Non-Current Deferred Tax Liability (2023 - 2025) Analysis & Trends
Invivyd has reported Non-Current Deferred Tax Liability for 3 years, with the latest figure at $719000.0 in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deferred Tax Liability rose 46.14% year-over-year to $719000.0; the trailing twelve-month figure through Dec 2025 stood at $719000.0 (up 46.14% YoY), and the FY2025 full-year result was $719000.0, up 46.14% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2025 stood at $719000.0, up from $492000.0 in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $719000.0 in Q4 2025, with the low at $492000.0 in Q4 2024.
- Historically, Non-Current Deferred Tax Liability has averaged $636666.7 across 3 years, with a median of $699000.0 in 2023.
- Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability slipped 29.61% — and 2025, when it jumped 46.14%.
- Invivyd's Non-Current Deferred Tax Liability stood at $699000.0 in 2023, then fell by 29.61% to $492000.0 in 2024, then soared by 46.14% to $719000.0 in 2025.
- The last three Non-Current Deferred Tax Liability figures came in at $719000.0 (Q4 2025), $492000.0 (Q4 2024), and $699000.0 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 719,000.00 |
| Dec 31, 2025 | 719,000.00 |
| Dec 31, 2024 | 492,000.00 |
| Dec 31, 2024 | 492,000.00 |
| Dec 31, 2023 | 699,000.00 |
| Dec 31, 2023 | 699,000.00 |